Effect of PTK/ZK on the angiogenic switch in head and neck tumors

Journal of Dental Research

Volumn 87, Issue 12, 2008, Pages 1166-1171

  Miyazawa, M ^a,b   Dong, Z ^a   Zhang, Z ^a   Neiva, K G ^a   Cordeiro, M M ^a   Oliveira, D T ^b   Nor, J E ^a,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angiogenesis; Cancer; Developmental therapeutics; Neovascularization

Indexed keywords

ANGIOGENESIS INHIBITOR; INTERLEUKIN 8; PHTHALAZINE DERIVATIVE; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; VASCULOTROPIN RECEPTOR; VATALANIB;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; COCULTURE; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; HEAD AND NECK TUMOR; HUMAN; MICROVASCULATURE; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; VASCULARIZATION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-8; MICE; MICE, SCID; MICROVESSELS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 58149400367     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910808701213     Document Type: Article

References (30)

1. Bergers G, Benjamin LE (2003). Tumorigenesis and the angiogenic switch, Nat Rev Cancer 3:401-410.
2. Carmeliet P (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3):4-10.
3. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5:1369-1379.
4. Drevs J, Hofmann 1, Hugenschmidl H, Willig C, Madjar H, Müller M, et al. (2000). Effects of PTK787/ZK. 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819-4824.
5. Drevs J, Zirrgiebel U, Schmidt-Gersbaeh CIM, Mross K, Medinger M, Lee L, el al. (2005) Soluble markers for the assessment of biological activity with PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16:558-565.
6. Ferrara N (2005). The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 94:209-231.
7. Ferrari N, Morini M, Pfeffer U, Minghelli S, Noonan DM, Albini A (2003). Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clin Cancer Res 9(16 Pt l):6020-6029.
8. Folkman J (1971). Tumor angiogenesis: therapeutic implications. New Engl J. Med 285:1182-1186.
9. Folkman J, Kalluri R (2004). Cancer without disease. Nature 427:787.
10. Genden EM, Ferlito A, Bradley PJ, Rinaldo A, Scully C (2003). Neck disease and distant metastases. Oral Oncol 39:207-212.
11. Gerber HP, Dixit V, Ferrara N (1998). Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bel-2 and A1 in vascular endothelial cells. J Biol Chem 273:13313-13316.
12. Hanahan D, Folkman J (1996). Patterns and emerging mechanisms of the ngiogenic switch during tumorigenesis. Cell 86:353-364.
13. Hess-Stumpp H, Habcrey M, Thicrauch KH (2005), PTK787/ZK222584. a tyrosine kinase inhibitor of all known YEGF receptors, represses tumor growth with high efficacy. Chem Biochem 6:550-557.
14. Jain H, Nör JE, Jackson T (2008). Investigating the VEGF-Bel-2-CXCL8 pathway in intratumoral angiogenesis: a quantitative approach. Bull Math Biol 70:89-117.
15. Kaneko T, Mantellini MG, Karl E, Zeitlin B, Verhaegen M, Soengas MS, et al. (2007), Bcl-2 orchestrates a crosstalk between endothelial cells and tumor cells that promotes tumor growth. Cancer Res 67:9685-9693.
16. Karl E, Warner K, Zeitlin B Kaneko T, Wurtzel L, Jin T, et al, (2005) Bcl-2 acts in a pro-angiogenic signaling pathway through Nuclear Factor-kb and CXC chemokines. Cancer Res 65: 5063-5069.
17. Kim S, Yazici YD, Barber SE, Jasser SA, Mandai M, Bekele BN, et al. (2006). Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK.222584 and CPT-11 Head Neck 28:389-399.
18. Lingen MW (1999). Angiogencsis in the development of head and neck cancer and its inhibition by ehemopreventive agents. Crit Rev Oral Biol Med 10:153-164.
19. Los M, Roodhart JM, Voest EE (2007). Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12:443-450.
20. Naumov GN, Akslcn LA, Folkman J (2006), Role of angiogencsis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5:1779-1787.
21. Noonan DM, Benelli R, Albini A (2007). Angiogencsis and cancer prevention: a vision. Recent Results Cancer Res 174:219-224.
22. Nör JE, Christensen J, Mooney DJ, Polverini PJ (1999). Vascular endothelial growth factor (VEGF)-mcdiated angiogencsis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154:375-384.
23. Nör JE, Christensen J, Liu J, Peters M, Mooney DJ, Stricter RM, et al. (2001a). Uprcgulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogencsis and accelerates tumor growth. Cancer Res 61:2183-2188.
24. Nör JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, et al. (2001b). Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 81:453-463.
25. Reed JC (2006). Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 13:1378-1386.
26. Singh RP, Agarwal R (2006). Mechanisms of action of novel agents for prostate cancer chemoprevention. Eadocr Relat Cancer 13:751-778.
27. Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J, et al. (2001). Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16:359-370.
28. Steeghs N, Nortier JW, Gelderblom H (2007). Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 14:942-953.
29. Wood J, Bold G, Buchdungcr E, Cozens R, Ferrari S, Frei J, et al. (2000). PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189.
30. Yazici YD, Kim S, Jasser SA, Wang Z, Carter KB Jr, Bucana CD, et al. (2005). Antfvascular therapy of oral tongue squamous cell carcinoma with PTK787. Laryngoscope 115:2249-2255.